Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 54-16 METEORA-II 

A randomized phase III trial of metronomic oral vinorelbine  plus cyclo­phos­phamide and capecitabine (VEX) versus weekly paclitaxel as first-line treatment in patients with ER-positive/HER2-negative advanced or metastatic breast cancer

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Elisabetta Munzone (IEO Milan, Italy)

Statistician
Zhuoxin Sun, PhD

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Colleen King

Trial contact in Italy:
Raffaella Ghisini, MSc

Data Manager
Colleen King

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg54_meteora@fstrf.org

Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: meteora-monitoring@ibcsg.org

Date of Activation
July 25, 2016

Targeted Accrual
160


News

09.09.2018:
9.9.2018 - RACE FOR LIFE, Bundesplatz Bern

19.06.2018:
PINK GOLFTOUR 2018  

10.06.2018:
32. SCHWEIZER FRAUENLAUF woman 4 woman - walking together, stronger than ever

All News

 
  Print